ES2158943T3 - Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos. - Google Patents

Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos.

Info

Publication number
ES2158943T3
ES2158943T3 ES95914792T ES95914792T ES2158943T3 ES 2158943 T3 ES2158943 T3 ES 2158943T3 ES 95914792 T ES95914792 T ES 95914792T ES 95914792 T ES95914792 T ES 95914792T ES 2158943 T3 ES2158943 T3 ES 2158943T3
Authority
ES
Spain
Prior art keywords
precursor
peptides derived
same
tumor rejection
rejection antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914792T
Other languages
English (en)
Inventor
Cornelis J M Melief
M W Visseren
W M Kast
Der Bruggen Pierre Van
Thierry Boon-Falleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Universiteit Leiden
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
Universiteit Leiden
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Universiteit Leiden, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2158943T3 publication Critical patent/ES2158943T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION DESCRIBE PEPTIDOS DERIVADOS DEL PRECURSOR MAGE NEN A LAS MOLECULAS HLA AN LA PRODUCCION DE CELULAS T CITOLITICAS. LOS "CTLS" RESULTANTES SON ESPECIFICOS PARA COMPLEJOS DE HLA OS COMPLEJOS PUEDEN UTILIZARSE PARA GENERAR ANTICUERPOS MONOCLONALES. LAS CELULAS T CITOLITICAS PRODUCIDAS PUEDEN UTILIZARSE EN EL CONTEXTO DE LA INMUNOTERAPIA, COMO EN UNA TRANSFERENCIA ADOPTIVA.
ES95914792T 1994-03-24 1995-03-21 Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos. Expired - Lifetime ES2158943T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/217,188 US5554724A (en) 1994-03-24 1994-03-24 Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

Publications (1)

Publication Number Publication Date
ES2158943T3 true ES2158943T3 (es) 2001-09-16

Family

ID=22810016

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914792T Expired - Lifetime ES2158943T3 (es) 1994-03-24 1995-03-21 Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos.

Country Status (17)

Country Link
US (3) US5554724A (es)
EP (1) EP0810870B1 (es)
JP (1) JP3360137B2 (es)
CN (1) CN1149257A (es)
AT (1) ATE201214T1 (es)
AU (1) AU682597B2 (es)
CA (1) CA2186006A1 (es)
DE (1) DE69520959T2 (es)
DK (1) DK0810870T3 (es)
ES (1) ES2158943T3 (es)
FI (1) FI963780L (es)
GR (1) GR3036320T3 (es)
NO (1) NO963918L (es)
NZ (2) NZ283561A (es)
PT (1) PT810870E (es)
WO (1) WO1995025530A1 (es)
ZA (1) ZA952375B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
CA2251781A1 (en) * 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
CN1313481C (zh) * 1997-06-23 2007-05-02 路德维格癌症研究所 结合hla分子的分离的九肽和十肽及其应用
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
AU765733B2 (en) * 1998-07-28 2003-09-25 Kyogo Itoh HLA-A2 restraint tumor antigen peptide originating in SART-1
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US8637305B2 (en) * 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
EP1864691B1 (en) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
ES2456666T3 (es) 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
AU2010298025B2 (en) 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
KR20140016315A (ko) 2011-03-07 2014-02-07 크리에이티브 네일 디자인 인코포레이티드 Uv-경화성 미용 손톱 코팅제를 위한 조성물 및 방법
CN104271612B (zh) 2012-03-15 2017-02-22 埃克森美孚化学专利公司 聚乙烯的氧整理
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

Also Published As

Publication number Publication date
EP0810870A1 (en) 1997-12-10
AU682597B2 (en) 1997-10-09
FI963780A0 (fi) 1996-09-23
NO963918L (no) 1996-11-20
DK0810870T3 (da) 2001-07-23
EP0810870B1 (en) 2001-05-16
AU2189395A (en) 1995-10-09
JPH10502329A (ja) 1998-03-03
FI963780A7 (fi) 1996-09-23
CN1149257A (zh) 1997-05-07
US6147187A (en) 2000-11-14
ZA952375B (en) 1995-12-15
DE69520959T2 (de) 2002-03-28
JP3360137B2 (ja) 2002-12-24
ATE201214T1 (de) 2001-06-15
FI963780L (fi) 1996-09-23
NZ283561A (en) 1998-04-27
NZ329695A (en) 2000-05-26
US5554724A (en) 1996-09-10
US6063900A (en) 2000-05-16
GR3036320T3 (en) 2001-11-30
EP0810870A4 (en) 1998-11-25
DE69520959D1 (de) 2001-06-21
NO963918D0 (no) 1996-09-19
PT810870E (pt) 2001-09-28
WO1995025530A1 (en) 1995-09-28
CA2186006A1 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
ES2158943T3 (es) Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos.
Castelli et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer
ES2174931T3 (es) Anticuerpos monoclonales que se unen al precursor del antigeno de rechazo de tumores mage-1, mage-1 recombinante y peptidos inmunogenos derivados de mage-1.
CO4810234A1 (es) Vacunas para el tratamiento de virus papiloma humano
ES2154728T3 (es) Peptidos aislados derivados de precursores del antigeno de rechazo de tumores mage que forman un complejo con moleculas del hla-a2.
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
Kobayashi et al. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase
ES2104565T3 (es) Determinantes anti-receptor de celulas t como tratamiento de enfermedades autoinmunes.
ES2135051T3 (es) Peptidos derivados de mage-3, aislados, que forman complejos con moleculas hla-a2 y usos de los mismos.
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
ES2134797T3 (es) Peptidos y fragmentos de peptidos terapeuticamente utiles.
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
JP2020534313A5 (es)
AR038700A1 (es) Anticuerpos monoclonales anti-tenascina humana
ES2123558T3 (es) Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc.
ES2126145T3 (es) Redireccionamiento de anticuerpos.
Brimnes et al. Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion
Benlalam et al. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients
ITRM920350A1 (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
Christensen et al. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1. 24
EA200702202A1 (ru) Идентификация представленных hla-a2 т-клеточных эпитопов, полученных из раково-эмбрионального антиген-незрелого рецепторного белка ламинила, и их применение
Lewis et al. Definition of tumor antigens suitable for vaccine construction
Voskens et al. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 810870

Country of ref document: ES